Search

The purpose of this work was to fabricate an electrochemical DNA biosensor for detecting hepatitis B virus. Gold nanorods (GNRs), which are known for their conductivity, were used to increase surface area and consequently increase the immobilization of single-stranded DNA (ss-DNA) on the modified gold electrode. The GNRs were characterized via transmission electron microscopy. The morphology of the gold electrode before and after modification with GNRs was characterized by scanning electron microscopy. Atomic-force microscopy was used to evaluate the morphology of the GNR electrode surface before and after interaction with ss-DNA. Cyclic voltammetry was used to monitor DNA immobilization and hybridization, using [Co(phen)] as an electrochemical indicator. The target DNA sequences were quantified at a linear range from 1.0 × 10 to 10.0 × 10 mol L, with a detection limit of 2.0 × 10 mol L by 3 σ. The biosensor had good specificity for distinguishing complementary DNA in the presence of non-complementary and mismatched DNA sequences. [ABSTRACT FROM AUTHOR]

Abstract An early on-time detection of breast cancer can effectively affect the outcome of the treatment. Here, we developed an ultrasensitive, simple and reliable immunosensor to detect the lowest alteration of CA 15-3, the standard biomarker of breast cancer patients. The proposed immunosensor was achieved by modification of gold electrode by streptavidin to immobilize the biotinylated anti-CA 15-3 monoclonal antibody (mAb). Bovine serum albumin was used to prevent nonspecific binding. To improve the sensitivity of modified immunosensor, the sandwich signal enhancer consisting of streptavidin-coated magnetic beads conjugated with biotinylated horseradish peroxidase (HRP) and anti-CA 15-3 biotinylated mAb was applied. The electrochemical measurements were obtained in the presence of hydroquinone as a redox agent and H 2 O 2 as the activating agent of HRP. Under optimized condition and using square wave voltammetry, the lower limit of quantification was obtained as 15 × 10−6 U/mL and the linear CA 15-3 concentration range was 50–15 × 10−6 U/mL. While showing significant stability, the immunosensor displayed an excellent sensitivity and specificity for the detection of CA 15-3 even in the human serum as compared to the enzyme-linked immunosorbent assay (ELISA) as a gold standard method. Based on our findings, the engineered immunosensor is proposed as a robust diagnostic tool for the clinical determination of CA 15-3 and other cancer biomarkers. Highlights • An ultrasensitive and reliable immunosensor was developed for the detection of CA 15-3. • An enzymatic sandwich approach was applied to enhance the signals of the biosensor. • A significant lower limit of quantification was achieved. • An excellent performance of proposed immunosensor was observed compared to ELISA as the reference method. [ABSTRACT FROM AUTHOR]

The sensitive quantification of Human Epidermal growth factor Receptor 2 (HER2), as a key prognostic tumor marker, plays a critical role in screening, early diagnosis and management of breast cancer. This paper describes a sandwich-type immunoassay with silver signal enhancement strategy for highly sensitive detection of HER2. For this purpose, the target capturing step was designed by functionalization of 3-aminopropyltrimethoxysilane coated magnetite nanoparticles with antibody (antiHER2/APTMS-Fe 3 O 4 ), as a platform bioconjugate (PB), and immobilized at a bare GCE. Then, in the presence of label-free immunosensor, the PB was covered by magnetic gold nanoparticles self-assembled with thiolated antibodies (antiHER2/Hyd@AuNPs-APTMS-Fe 3 O 4 ) containing chemically reduced silver ions, as a label bioconjugate (LB). Under optimum conditions, a linear relationship between the differential pulse voltammetric (DPV) stripping signal of silver and the logarithm of HER2 concentrations was obtained in the range of 5.0 × 10 −4 -50.0 ng mL −1 (R 2 = 0.9906) with a detection limit of 2.0 × 10 −5 ng mL −1 . The effectiveness of this protocol was evaluated experimentally through employing of designed immunosensor for detection of the serum level of tumor marker. The good consistency of the results with those obtained by the enzyme-linked immunosorbent assay (ELISA) conventional method ( p- value of < 0.05) showed that this immunosensor can be applied for the testing of HER2 in clinical samples of breast cancer patients. [ABSTRACT FROM AUTHOR]